A5033029228- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cutaneous lymphoproliferative disorders research
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Glycosylation and Glycoproteins Research
- Histone Deacetylase Inhibitors Research
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- Chronic Myeloid Leukemia Treatments
- COVID-19 and healthcare impacts
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2016-2025
National Cancer Institute
2024
University of Milan
2024
Centro Hospitalar de Vila Nova de Gaia
2014-2023
Sapienza University of Rome
2023
University of Naples Federico II
1981-2020
Creative Commons
2020
Institute for Experimental Endocrinology and Oncology
1983-2020
National Research Council
2020
University of Rome Tor Vergata
2020
The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant prospective comparison two approaches.We randomly assigned 1623 to in 28-day cycles until disease progression (535 patients), same 72 weeks (18 cycles; 541 or MPT (547 patients). primary end point was progression-free survival continuous...
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured R-CHOP. Polatuzumab vedotin an antibody-drug conjugate targeting CD79b, which ubiquitously expressed on the surface malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate modified regimen R-CHOP (pola-R-CHP), in vincristine was replaced polatuzumab vedotin, as...
Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is the standard of care in previously untreated diffuse large B-cell lymphoma (DLBCL). Obinutuzumab (G) a glycoengineered, type II, anti-CD20 monoclonal antibody. GOYA was randomized phase III study that compared G-CHOP with R-CHOP patients advanced-stage DLBCL. Methods Patients (N = 1,418) were randomly assigned to receive eight 21-day cycles G (n 706) or R 712), six CHOP. Primary end point...
Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase activity of rituximab.A phase III, multicenter, randomized trial plus versus placebo was conducted in patients relapsed and/or refractory follicular or marginal zone lymphoma. received for 12 cycles once per week 4 weeks cycle 1 and day 2 through 5. The primary end...
Abstract The expression of CCL5/Rantes by Hodgkin (H) and Reed‐Sternberg (RS) cells has been recently documented. In the present study we demonstrated that CCL5 receptor (CCR5) is constitutively expressed Lymphoma (HL)‐derived cell lines ( i.e . L‐428, KM‐H2, L‐1236 L‐540) as shown immunohistochemistry, flow cytometry western blotting also detected immunohistochemistry on primary H‐RS from lymph node tissues. sCD40L never significantly affected CCR5 expression, whereas a short exposure to...
We report on a multicenter phase II trial of (90)yttrium-ibritumomab-tiuxetan ((90)YIT) as first-line stand-alone therapy for patients with follicular lymphoma (FL).Fifty-nine CD20(+) FL grade 1 to 3a in stages II, III, or IV, age 50 years old older requiring were enrolled. They received (90)YIT according standard procedure. If complete response (CR) unconfirmed (CRu) without evidence minimal residual disease (MRD) 6 months after application was achieved, observed further intervention. The...
Summary COVID‐19 is associated with high mortality in patients haematological malignancies (HM) and rate of seroconversion unknown. The ITA‐HEMA‐COV project (NCT04352556) investigated patterns for SARS‐CoV‐2 IgG HMs. A total 237 patients, PCR‐positive at least one test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid 54 (22·8%) plasma cell neoplasms. Overall, 69% (164 237) detectable serum antibodies. Serologically negative (31%, 73...
PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients follicular lymphoma who responded to induction immunochemotherapy. METHODS randomly assigned treatment-naïve, advanced-stage, high-tumor burden receive standard RM or on the basis metabolic response and molecular assessment minimal residual disease (MRD). The experimental arm used three types therapies: for complete (CMR) MRD-negative patients, observation; CMR MRD-positive...
Increasing evidence suggests that bone marrow-derived mesenchymal stem cells (MSCs) are recruited into the stroma of developing tumors where they contribute to cancer progression. MSCs produce different growth factors sustain tumor-associated neo-angiogenesis. Since majority carcinomas secrete ligands epidermal factor receptor (EGFR), we assessed role EGFR signaling in regulating release angiogenic MSCs. Treatment human primary and osteoblastic cell line hFOB with transforming α (TGF-α), one...
The clinical and pathological features of classical Hodgkin lymphoma (cHL) mirror an abnormal tissue systemic immune response due to the production a variety cytokines chemokines by malignant Hodgkin-Reed-Sternberg (H-RS) cells and/or surrounding reactive cells. Here, we demonstrate that HL-derived cell lines (L-428, KM-H2, HDLM-2, L-1236 L-540) primary H-RS from lymph node tissues HL patients express IL-7(R) receptor. IL-7 appears be involved in autocrine circuitries because L-1236, HDLM-2...